Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer
This review discusses the role of GLP-1 receptor agonists in improving glycemic control and promoting weight loss, and explores their potential anticancer effects by modulating pathways like insulin signaling, inflammation, and cellular proliferation. Current evidence from observational and secondary analyses suggests potential protective effects against several cancers, including prostate and breast cancer, through both weight-dependent and independent mechanisms. However, the absence of large-scale randomized controlled trials with cancer-specific endpoints remains a critical limitation, and safety concerns warrant vigilance.
What to check after reading
Evidence suggests potential protective effects, but large-scale RCTs are lacking and safety requires further verification.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.